查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492454

纤维囊性乳房诊断和治疗市场规模 - 按类型和最终用户 - 区域前景、竞争策略和细分市场预测（截至 2033 年）

Fibrocystic Breasts Diagnostics Treatment Market Size- By Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 211 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到2033年，全球纤维囊性乳房诊断和治疗市场规模将成长至311.7亿美元，复合年增长率为8.11%。

全球纤维囊性乳房诊断和治疗市场受到了 COVID-19 疫情的重大影响。为了优先考虑 COVID-19 患者并降低感染风险，许多非紧急治疗在疫情高峰期被取消或延迟。因此，纤维囊性乳房疾病患者可能会延迟诊断和治疗，导致併发症和疾病进展。

本报告调查了全球纤维囊性乳房诊断和治疗市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测，以及各个细分市场、地区和主要国家的详细分析、竞争格局、主要企业。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

  • 促进因素、抑制因素、机会与挑战分析
  • COVID-19 对市场的影响

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争状况

  • 製造地、销售区域、产品类型分布
  • 併购、联盟、产品发布、合作

第七章按类型分類的全球纤维囊性乳房诊断和治疗市场

  • 全球市场规模、份额和预测
  • 诊断
  • 乳房X光照相术
  • 乳房切片
  • 治疗
  • 药品
  • 乙酰胺酚
  • 非类固醇消炎剂
  • 细针穿刺法
  • 手术切除
  • 口服避孕药

第八章全球纤维囊性乳房诊断与治疗市场：依最终用户分类

  • 全球市场规模、份额和预测
  • 医院
  • 诊所
  • 诊断中心
  • 专科诊所/復健中心
  • 研究机构
  • 其他的

第九章 全球纤维囊性乳房诊疗市场预测

  • 市场规模/市场占有率

第10章按地区分類的全球纤维囊性乳房诊断及治疗市场

  • 市场规模/市场占有率趋势/预测
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美洲
  • 拉丁美洲

第十一章 公司简介

  • Argon Medical Devices
  • Becton, Dickinson and Company
  • Bayer AG
  • Boston Scientific Corp.
  • Devicor Medical Products Inc.
  • Johnson & Johnson Pvt. Ltd.
  • Merck
  • Sanofi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd.
  • 其他的

第十二章 结论

第十三章简称

第14章参考链接

简介目录
Product Code: HLCA2458

Fibrocystic Breasts Diagnostics Treatment Market Introduction and Overview

According to SPER market research, 'Fibrocystic Breasts Diagnostics Treatment Market Size- By Types, By End-Users - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Fibrocystic Breasts Diagnostics Treatment Market is predicted to reach USD 31.17 billion by 2033 with a CAGR of 8.11%.

Breasts feeling lumpy are a symptom of fibrocystic breast disease, a non-cancerous illness also called fibrocystic change or fibrocystic breasts. The breast lumps are caused by fibrocystic changes. These lumps develop from a concentration of fibrous tissue in one area of the breast. Changes in breast tissue brought on by fluctuations in hormone levels produced by the ovaries are the cause of fibrocystic breasts.

The worldwide market for fibrocystic breast diagnosis and therapy has been greatly influenced by the COVID-19 epidemic. Many non-urgent medical treatments were canceled or postponed during the peak of the pandemic in order to prioritize COVID-19 patients and lower the risk of transmission. As a result, people who have fibrocystic breast disorders might have had delays in their diagnosis and course of treatment, which could have resulted in complications or the advancement of their illness.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Types, By End Users

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Argon Medical Devices, Becton,Dickson and Company, Bayer AG, Boston Scientific Corp, Devicor Medical Products Inc., Johnson & Johnson Pvt. Ltd., Merck, Sanofi, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd.

Global Fibrocystic Breasts Diagnostics Treatment Market Segmentation:

By Types: Based on the Types, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Diagnosis, Mammogram, Breast Biopsy, Treatment, Medications, Acetaminophen. Non-steroidal anti-inflammatory Drugs, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptive

By End-Users: Based on the End-Users, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Hospitals, Clinics, Diagnostic Centers, Speciality Clinics and Rehab Centers, Research Institutes, Others.)

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Fibrocystic Breasts Diagnostics Treatment Market.

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Fibrocystic Breasts Diagnostics Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Fibrocystic Breasts Diagnostics Treatment Market

7. Global Fibrocystic Breasts Diagnostics Treatment Market, By Type (USD Million) 2020-2033

  • 7.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2020-2026
  • 7.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2027-2033
  • 7.3. Diagnosis
  • 7.4. Mammogram
  • 7.5. Breast Biopsy
  • 7.6. Treatment
  • 7.7. Medications
  • 7.8. Acetaminophen
  • 7.9. Non-steroidal Inflammatory Drugs
  • 7.10. Fine-needle Aspirations
  • 7.11. Surgical Excision
  • 7.12. Oral Contraceptives

8. Global Fibrocystic Breasts Diagnostics Treatment Market, By End-Users (USD Million)2020-2033

  • 8.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2020-2026
  • 8.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2027-2033
  • 8.3. Hospitals
  • 8.4. Clinics
  • 8.5. Diagnostic Centers
  • 8.6. Speciality Clinics and Rehab Centers
  • 8.7. Research Institutes
  • 8.8. Others

9. Global Fibrocystic Breasts Diagnostics Treatment Market Forecast, 2020-2033 (USD Million)

  • 9.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share

10. Global Fibrocystic Breasts Diagnostics Treatment Market, By Region, 2020-2033 (USD Million)

  • 10.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2020-2026)
  • 10.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2027-2033)
  • 10.3. Asia-Pacific
    • 10.3.1. Australia
    • 10.3.2. China
    • 10.3.3. India
    • 10.3.4. Japan
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. Europe
    • 10.4.1. France
    • 10.4.2. Germany
    • 10.4.3. Italy
    • 10.4.4. Spain
    • 10.4.5. United Kingdom
    • 10.4.6. Rest of Europe
  • 10.5. Middle East and Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Qatar
    • 10.5.4. South Africa
    • 10.5.5. Egypt
    • 10.5.6. Morocco
    • 10.5.7. Nigeria
    • 10.5.8. Rest of Middle East & Africa
  • 10.6. North America
    • 10.6.1. Canada
    • 10.6.2. Mexico
    • 10.6.3. United States
  • 10.7. Latin America
    • 10.7.1. Argentina
    • 10.7.2. Brazil
    • 10.7.3. Rest of Latin America

11. Company Profile

  • 11.1. Argon Medical Devices
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Becton, Dickinson and Company
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Bayer AG
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Boston Scientific Corp.
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Devicor Medical Products Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Johnson & Johnson Pvt. Ltd.
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Merck
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Sanofi
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Sun Pharmaceutical Industries
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Teva Pharmaceutical Industries Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links